Cargando…
An immunotherapy response prediction model derived from proliferative CD4(+) T cells and antigen-presenting monocytes in ccRCC
Most patients with clear cell renal cell carcinoma (ccRCC) have an impaired response to immune checkpoint blockade (ICB) therapy. Few biomarkers can predict responsiveness, and there is insufficient evidence to extend them to ccRCC clinical use. To explore subtypes and signatures of immunocytes with...
Autores principales: | Zheng, Kun, Gao, Lianchong, Hao, Jie, Zou, Xin, Hu, Xiaoyong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452905/ https://www.ncbi.nlm.nih.gov/pubmed/36091022 http://dx.doi.org/10.3389/fimmu.2022.972227 |
Ejemplares similares
-
Untangling ccRCC prognosis with SLINKY
por: Reinfeld, Bradley I., et al.
Publicado: (2017) -
CD44 Is Associated with Poor Prognosis of ccRCC and Facilitates ccRCC Cell Migration and Invasion through HAS1/MMP9
por: Du, Tan, et al.
Publicado: (2023) -
Functional and translational consequences of immunometabolic coevolution in ccRCC
por: Reznik, Ed, et al.
Publicado: (2023) -
Pivotal biomarker expression and drug screening in advanced ccRCC
por: Xiao, Wen, et al.
Publicado: (2020) -
SDHB Suppresses the Tumorigenesis and Development of ccRCC by Inhibiting Glycolysis
por: Fang, Zhiyu, et al.
Publicado: (2021)